# Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System

> **NCT00520130** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 92 (actual)

## Conditions studied

- Myelodysplastic Syndrome
- Hodgkin's Lymphoma
- Non-Hodgkin's Disease
- Acute Leukemia
- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** Rituximab
- **DRUG:** Cyclosporine
- **DRUG:** Allogenic stem cell transplant (ASCT)
- **DRUG:** Conditioning Chemotherapy
- **DRUG:** TMS
- **DRUG:** FLAG
- **DRUG:** EPOCH-F
- **BIOLOGICAL:** Alemtuzumab

## Key facts

- **NCT ID:** NCT00520130
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10-30
- **Primary completion:** 2015-10-14
- **Final completion:** 2018-12-31
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2019-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00520130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00520130, "Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00520130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*